ATE335072T1 - Methoden für inhibition der cd14-abhängigen zellaktivierung - Google Patents

Methoden für inhibition der cd14-abhängigen zellaktivierung

Info

Publication number
ATE335072T1
ATE335072T1 AT94920682T AT94920682T ATE335072T1 AT E335072 T1 ATE335072 T1 AT E335072T1 AT 94920682 T AT94920682 T AT 94920682T AT 94920682 T AT94920682 T AT 94920682T AT E335072 T1 ATE335072 T1 AT E335072T1
Authority
AT
Austria
Prior art keywords
cell activation
monoclonal antibodies
inhibition
methods
dependent cell
Prior art date
Application number
AT94920682T
Other languages
English (en)
Inventor
Didier J Leturcq
Ann M Moriarty
Richard J Ulevitch
Peter S Tobias
John C Mathison
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE335072T1 publication Critical patent/ATE335072T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50—Lipopolysaccharides; LPS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
AT94920682T 1993-05-28 1994-05-27 Methoden für inhibition der cd14-abhängigen zellaktivierung ATE335072T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7016093A 1993-05-28 1993-05-28

Publications (1)

Publication Number Publication Date
ATE335072T1 true ATE335072T1 (de) 2006-08-15

Family

ID=22093518

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94920682T ATE335072T1 (de) 1993-05-28 1994-05-27 Methoden für inhibition der cd14-abhängigen zellaktivierung

Country Status (8)

Country Link
US (3) US5820858A (de)
EP (1) EP0751962B1 (de)
JP (4) JPH08510909A (de)
AT (1) ATE335072T1 (de)
AU (1) AU695124B2 (de)
CA (1) CA2163976C (de)
DE (1) DE69434812D1 (de)
WO (1) WO1994028025A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163976C (en) * 1993-05-28 2010-06-29 Didier J. Leturcq Methods and compositions for inhibiting cd14 mediated cell activation
JP3892902B2 (ja) * 1994-09-16 2007-03-14 ザ スクリップス リサーチ インスティチュート グラム陽性細菌及びマイコバクテリアの作用を阻止するための抗体の使用
CA2208233A1 (en) * 1994-12-23 1996-07-04 Laboratories Om S.A. Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
AU5688596A (en) * 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
ID26730A (id) * 1998-05-27 2001-02-01 Gemma Biotechnology Ltd Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
EP1213586A4 (de) * 1999-09-17 2003-02-05 Mochida Pharm Co Ltd Verfahren zum fraktionierten messen von löslichem cd14-protein
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
US7264967B2 (en) 2000-11-22 2007-09-04 Mochida Pharmaceutical Co., Ltd. Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding
EP1478667B1 (de) * 2002-02-26 2010-09-08 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Monoklonaler anti-mensch-tenascin-Antikörper
US7608684B2 (en) * 2002-11-12 2009-10-27 Mochida Pharmaceuticals Co., Ltd. Soluble CD14 antigen
MXPA05011886A (es) 2003-05-15 2006-02-17 Tanox Inc Metodos y composiciones para la prevencion y tratamiento de septicemia.
WO2005054493A2 (en) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Altered activity of toll-like receptors
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
DE602005021694D1 (de) * 2004-12-10 2010-07-15 Novimmune Sa Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
US8252905B2 (en) * 2005-06-03 2012-08-28 Mochida Pharmaceutical Co., Ltd. Anti-CD14 antibody fusion protein
DK2173381T3 (da) 2007-05-14 2013-12-02 Novimmune Sa Fc-receptor bindende polypeptider med modificerede effektorfunktioner
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
PL3939617T3 (pl) 2009-02-13 2025-03-17 Immunomedics, Inc. Związki pośrednie do wytwarzania koniugatów z wiązaniem rozszczepialnym wewnątrzkomórkowo
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
BR112015013444B1 (pt) 2012-12-13 2022-11-01 Immunomedics, Inc Uso de um imunoconjugado
EP3107577B1 (de) 2014-02-21 2024-03-20 IBC Pharmaceuticals, Inc. Krankheitstherapie durch induktion einer immunantwort gegen trop-2-exprimierende zellen
EP3110445A4 (de) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanisierter rfb4-anti-cd22-antikörper
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
EP3286224A4 (de) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
CN107735104B (zh) 2015-06-25 2022-05-03 免疫医疗公司 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018165720A1 (en) * 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3612566A4 (de) * 2017-04-21 2021-03-03 Implicit Bioscience Limited Cd14-antagonist-antikörper zur behandlung von neurodegenerativen erkrankungen
TWI726228B (zh) * 2017-08-09 2021-05-01 國立臺灣大學 Ｃｄ１４拮抗分子用於治療癌症
US11908581B2 (en) 2018-04-10 2024-02-20 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
US11504071B2 (en) 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
KR20210014109A (ko) 2018-05-10 2021-02-08 더 메서디스트 하스피틀 질환의 예후와 관리 방법
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021016601A1 (en) 2019-07-25 2021-01-28 Implicit Bioscience Limited Methods and agents for treating acute neuroinflammatory injury
US20220324960A1 (en) * 2019-08-29 2022-10-13 Kindred Biosciences, Inc. Anti-IL31 Antibodies for Veterinary Use
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021243396A1 (en) * 2020-06-01 2021-12-09 Implicit Bioscience Limited Therapeutic methods of using cd 14 antagonistic antibodies in treating conditions associated with a coronavirus infection including sars-cov-2 (covid-19)
EP4092051A4 (de) * 2020-06-18 2023-09-06 Shenzhen Mindray Bio-Medical Electronics Co., Ltd Antilöslicher cd14-subtyp-antikörper, kit und dessen verwendung
US20250276059A1 (en) * 2020-09-10 2025-09-04 Implicit Bioscience Limited Therapeutic methods and agents for the treatment of myocardial infarction
CN116710135A (zh) 2020-10-07 2023-09-05 6线生物技术公司 用于治疗眼部疾病的方法和试剂
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
WO2025014712A2 (en) * 2023-07-07 2025-01-16 Villanelle Life Science Inc Antibodies against cd14 and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1991001639A1 (en) * 1989-08-01 1991-02-21 Scripps Clinic And Research Foundation Methods and compositions for ameliorating the symptoms of sepsis
CA2163976C (en) * 1993-05-28 2010-06-29 Didier J. Leturcq Methods and compositions for inhibiting cd14 mediated cell activation
US5705398A (en) * 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding

Also Published As

Publication number Publication date
US20060073145A1 (en) 2006-04-06
JP2004168787A (ja) 2004-06-17
EP0751962A4 (de) 1997-05-21
JPH08510909A (ja) 1996-11-19
EP0751962B1 (de) 2006-08-02
AU7138494A (en) 1994-12-20
CA2163976A1 (en) 1994-12-08
JP2008163039A (ja) 2008-07-17
DE69434812D1 (de) 2006-09-14
CA2163976C (en) 2010-06-29
WO1994028025A1 (en) 1994-12-08
US6444206B1 (en) 2002-09-03
EP0751962A1 (de) 1997-01-08
JP2009278979A (ja) 2009-12-03
US7326569B2 (en) 2008-02-05
AU695124B2 (en) 1998-08-06
US5820858A (en) 1998-10-13

Similar Documents

Publication Publication Date Title
ATE335072T1 (de) Methoden für inhibition der cd14-abhängigen zellaktivierung
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
NO961706L (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
IL138497A0 (en) Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
ATE208820T1 (de) Humanisierte antikoerper
EP1054693B8 (de) Inhibitoren der komplement-aktivierung
FR2729570B1 (de)
MY105946A (en) Antagonists of gm-csf derived from the carboxyl terminus.
UA86768C2 (ru) ХИМЕРНОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, ПОЛУЧЕННОЕ ИЗ МЫШИНОГО АНТИИДИОТИПИЧНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА 1Е10, КОТОРОЕ РАСПОЗНАЕТ МЫШИНОЕ MAbР3
EP0189688A3 (de) Zum Erkennen von Adernverkalkungsschäden fähiger monoklonaler Antikörper und Mittel zum Nachweis und zur Behandlung von Adernverkalkung
DE69125485D1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
GR3029483T3 (en) Antibodies against t-cells as therapeutics
ATE120233T1 (de) Monoklonale antikörper, b-spezifisch für apolipoprotein, die von zwei hybridomen erzeugt werden.
DE69327059D1 (de) Verfahren zur herstellung von testelementen
GR3031607T3 (en) Selective system scan for multizone radiotelephone subscriber units.
Zocchi et al. Involvement of CD56/N-CAM molecule in the adhesion of human solid tumor cell lines to endothelial cells
MX9804459A (es) Procedimiento para el diagnostico y terapia de epitelioma.
GB9319877D0 (en) Novel hybridoma & monoclonal antibodies produced thereby
BG96346A (bg) Специфични свързващи вещества
DE60331882D1 (de) Antikörper zur Identifizierung und/oder Isolierung von wenigstens einer Zellpopulation ausgewählt aus hämatopoetischen Stammzellen, neuronalen Stammzellen, progenitoren neuronalen Zellen, Mesenchym-Stammzellen und mesenchym-progenitoren Stammzellen
ATE346865T1 (de) Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
ATE90381T1 (de) Monoklonale antikoerper und verfahren zum nachweis von pathogenen pilzen.
DK1079856T3 (da) Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme
CA2137551A1 (en) A novel endothelial cell molecule mediating lymphocyte binding in man
PT99114A (pt) Processo para a preparacao de anticorpos monoclonais dirigidos contra complexos formados por trombina e inibidores de trombina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties